Floatz logo

Intranasal Modified Temozolomide

Astrocytoma of Brain

Center Trials & Treatment EuropePhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the Astrocytoma of Brain cohort.

Asset / SponsorPhaseRating
coq10
Seema Nagpal
Phase 1CC
Lomustine
Jasper Gerritsen
D
Triapine
National Cancer Institute (NCI)
Phase 1NR

Same molecule, other indications

Intranasal Modified Temozolomide is also rated in:

malignant gliomaDormant
CC
Indicative ·
44 / 100
View asset →
gliosarcomaDormant
CC
Indicative ·
44 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →